|Solubility||Soluble in DMSO.|
|Declaration||Manufactured by SynKinase.|
|Other Product Data||
Target: CDK4/CDK6 | Kinase Group: CGMC | Substrate: Serine-Threonine
Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
|Use/Stability||Stable for at least 2 years after receipt when stored at -20°C.|
|Product Specification Sheet|
Orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathways, with potential antineoplastic activity. Specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation.
- Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma: J. Rader, et al.; Clin. Cancer Res. 19, 6173 (2013)
- Molecular pathways: CDK4 inhibitors for cancer therapy: M.A. Dickson; Clin. Cancer Res. 20, 3379 (2014)
- Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivo: Y.X. Zhang, et al.; Mol. Cancer Ther. 13, 2184 (2014)